Mometasonfuroaat Cipla (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasonfuroaat Cipla, is a corticosteroid presented as an inhalation product for respiratory use. It is used to reduce airway inflammation in patients with asthma and related respiratory conditions, helping to improve breathing and control symptoms.

GNH USA supplies Mometasonfuroaat Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. This enables reliable access to essential respiratory therapy across diverse markets.

Mometasone furoate inhalation acts on airway inflammation in respiratory disease. - Asthma: Improves lung function and reduces frequency of symptoms by controlling airway inflammation. - Allergic rhinitis: Decreases nasal congestion and itching when administered as a nasal spray formulation. - COPD: Helps reduce exacerbations by lowering airway inflammation in chronic obstructive pulmonary disease.

Mometasone furoate inhalation may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Throat irritation: mild soreness or scratchy feeling in the throat. - Hoarseness: change in voice quality, especially after use. - Oral candidiasis: fungal infection in the mouth, often presenting as white patches. - Cough: transient coughing after inhalation.

Serious or Rare Side Effects: - Adrenal suppression: reduced cortisol production with prolonged high‑dose use. - Pneumonia: lower respiratory infection that may require medical attention. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria.

Before prescribing Mometasone furoate inhalation, clinicians should consider several precautionary measures. - Assess infection: Evaluate for active respiratory infections before initiating therapy. - Monitor growth: In pediatric patients, regularly assess growth velocity during long‑term use. - Use spacer: Recommend a spacer device to reduce oropharyngeal deposition. - Avoid abrupt discontinuation: Taper the dose when stopping long‑term therapy to prevent adrenal insufficiency. - Review concomitant drugs: Check for medications that may affect glucocorticoid metabolism. - Store at ambient temperature: Keep in original container, protect from moisture and heat.

Mometasone furoate inhalation can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase systemic glucocorticoid exposure. - Systemic glucocorticoids: Combined use can enhance risk of adrenal suppression and other steroid‑related effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): May reduce inhaled steroid efficacy. - Antifungal azoles (e.g., fluconazole): Can modestly raise mometasone levels. - Diabetic medications: Inhaled steroids may affect glucose control, requiring monitoring.